Related Experiment Video
Updated: May 17, 2026
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Experimental biomarkers in heart failure: an update
Jeremy Kobulnik1, Diego Delgado
1Toronto General Hospital/University of Toronto, Toronto, ON, Canada.
Expert Review of Cardiovascular Therapy
|October 27, 2012
Summary
Researchers are exploring new heart failure biomarkers beyond B-type natriuretic peptide. These novel markers, from various pathways, offer independent prognostic insights and may predict treatment response, improving risk assessment.
Area of Science:
- Cardiology
- Biomarker Discovery
- Heart Failure Research
Background:
- Current heart failure management relies on B-type natriuretic peptide and clinical assessment.
- There is a need for novel biomarkers to complement existing diagnostic and prognostic tools.
- Experimental biomarkers from diverse pathophysiological categories are under investigation.
Purpose of the Study:
- To evaluate the utility of experimental heart failure biomarkers.
- To identify biomarkers that provide prognostic information independent of current assessments.
- To explore biomarkers that predict response to specific therapies.
Main Methods:
- Review of research over the past 5 years on candidate heart failure biomarkers.
- Identification of biomarkers across categories: inflammation, myocyte necrosis, renal dysfunction, neurohumoral activation, oxidative stress, and intracardiac pressure.
- Analysis of biomarker data for independent prognostic value and prediction of therapy response.
Main Results:
- Several experimental biomarkers offer prognostic information independent of conventional methods.
- Some biomarkers help identify dominant pathologies, potentially predicting therapy responsiveness.
- Preliminary data support the development of integrated biomarker profiling models for refined risk assessment.
Conclusions:
- Experimental biomarkers show promise in complementing B-type natriuretic peptide for heart failure management.
- Novel biomarkers can enhance risk stratification and personalize treatment strategies.
- Comprehensive biomarker profiling may significantly improve heart failure risk assessment and patient outcomes.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...